- Home
- CCBG vs KROS Comparison
CCBG vs KROS Comparison
Compare CCBG & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCBG
- KROS
- Stock Information
- Founded
- CCBG 1895
- KROS 2015
- Country
- CCBG United States
- KROS United States
- Employees
- CCBG N/A
- KROS N/A
- Industry
- CCBG Major Banks
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- CCBG Finance
- KROS Health Care
- Exchange
- CCBG Nasdaq
- KROS Nasdaq
- Market Cap
- CCBG 620.5M
- KROS 589.8M
- IPO Year
- CCBG N/A
- KROS 2020
- Fundamental
- Price
- CCBG $36.00
- KROS $10.86
- Analyst Decision
- CCBG Buy
- KROS Buy
- Analyst Count
- CCBG 3
- KROS 11
- Target Price
- CCBG $38.50
- KROS $45.33
- AVG Volume (30 Days)
- CCBG 30.3K
- KROS 2.0M
- Earning Date
- CCBG 01-28-2025
- KROS 02-26-2025
- Dividend Yield
- CCBG 2.44%
- KROS N/A
- EPS Growth
- CCBG 3.04
- KROS N/A
- EPS
- CCBG 3.04
- KROS N/A
- Revenue
- CCBG $226,023,000.00
- KROS $651,000.00
- Revenue This Year
- CCBG N/A
- KROS $303.39
- Revenue Next Year
- CCBG $3.63
- KROS N/A
- P/E Ratio
- CCBG $11.84
- KROS N/A
- Revenue Growth
- CCBG 4.47
- KROS 8037.50
- 52 Week Low
- CCBG $25.45
- KROS $9.78
- 52 Week High
- CCBG $40.86
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- CCBG 47.41
- KROS 20.25
- Support Level
- CCBG $35.04
- KROS $9.78
- Resistance Level
- CCBG $36.69
- KROS $16.49
- Average True Range (ATR)
- CCBG 0.95
- KROS 0.92
- MACD
- CCBG 0.06
- KROS 0.97
- Stochastic Oscillator
- CCBG 68.81
- KROS 14.52
About CCBG Capital City Bank Group
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services among others through its banking offices in Florida, Georgia, and Alabama.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.